Sera Prognostics, Inc. (SERA) Stock

Sera Prognostics, Inc. (SERA) is a Healthcare stock trading at $1.80 (as of 2026-06-18), with a market capitalization of $108.56M and a trailing P/E of -3.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sera Prognostics, Inc. develops and commercializes biomarker-based diagnostic tests aimed at pregnancy outcomes. Its PreTRM blood-based test is designed to assess risk of spontaneous preterm birth in asymptomatic singleton pregnancies, and it is advancing additional product candidates for conditions such as preeclampsia, gestational diabetes, and fetal growth restriction.

Valuation — source: SEC EDGAR (first-party)
Price	$1.80
Market Cap	$108.56M
P/E Ratio	-3.4
EV / EBITDA	-2.9
Price / Book	1.61
Price / Sales	1904.55
DCF Value (model)	$-9.33
DCF Upside vs Price	-618.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$81000.00
Net Margin	-39417.3%
Return on Equity	-47.5%
Current Ratio	2.12
Revenue Growth (YoY)	5.2%
EPS Growth (YoY)	-32.3%
FCF Growth (YoY)	85.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.33 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.4
Sector P/E (Healthcare)	21.0
Industry P/E (Healthcare Services)	23.0
vs Sector	-116.1%
vs Industry	-114.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($11.16M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Healthcare Services
CEO	Zhenya Lindgardt
Employees	63
Country	US
IPO Date	2021-07-15

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.